Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions. The company also provides neuroscience products for the treatment of depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorder; obsessive-compulsive disorder, bulimia nervosa, and panic disorder; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains, as well as immunology products to treat Alzheimer's disease. In addition, it offers oncology products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products to treat erectile dysfunction and benign prostatic hyperplasia; and migraine. Further, the company provides animal health products, such as cattle feed additives; protein supplements for cows; leanness and performance enhancers for swine and cattle; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; anticoccidial agents for poultry use; and chewable tablets that kill fleas and prevent heartworm diseases. Additionally, it offers vaccines to prevent bordetella, Lyme disease, rabies, and parvovirus. The company has collaboration agreements with Daiichi Sankyo Co., Ltd.; Incyte Corporation; Pfizer Inc.; AstraZeneca; and Nektar Therapeutics, as well as has strategic collaboration with Sigilon Therapeutics. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNYSE:LLY
CUSIP53245710
Phone317-276-2000
Debt
Debt-to-Equity Ratio0.64
Current Ratio1.41
Quick Ratio1.01
Price-To-Earnings
Trailing P/E Ratio20.91
Forward P/E Ratio17.49
P/E Growth1.54
Sales & Book Value
Annual Sales$22.87 billion
Price / Sales4.27
Cash Flow$5.6001 per share
Price / Cash16.08
Book Value$10.60 per share
Price / Book8.50
Profitability
EPS (Most Recent Fiscal Year)$4.28
Net Income$-204,100,000.00
Net Margins4.82%
Return on Equity35.37%
Return on Assets11.30%
Miscellaneous
Employees40,655
Outstanding Shares1,085,430,000
Market Cap$96,679.29
Eli Lilly And Co (NYSE:LLY) Frequently Asked Questions
What is Eli Lilly And Co's stock symbol?
Eli Lilly And Co trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."
How often does Eli Lilly And Co pay dividends? What is the dividend yield for Eli Lilly And Co?
Eli Lilly And Co declared a quarterly dividend on Monday, June 18th. Shareholders of record on Wednesday, August 15th will be given a dividend of $0.5625 per share on Monday, September 10th. This represents a $2.25 annualized dividend and a yield of 2.50%. The ex-dividend date of this dividend is Tuesday, August 14th. View Eli Lilly And Co's Dividend History.
How were Eli Lilly And Co's earnings last quarter?
Eli Lilly And Co (NYSE:LLY) issued its earnings results on Tuesday, April, 24th. The company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.13 by $0.21. The business had revenue of $5.70 billion for the quarter, compared to analysts' expectations of $5.51 billion. Eli Lilly And Co had a net margin of 4.82% and a return on equity of 35.37%. The business's quarterly revenue was up 9.0% compared to the same quarter last year. During the same period last year, the company earned $0.98 EPS. View Eli Lilly And Co's Earnings History.
When is Eli Lilly And Co's next earnings date?
What guidance has Eli Lilly And Co issued on next quarter's earnings?
Eli Lilly And Co updated its FY18 earnings guidance on Tuesday, April, 24th. The company provided earnings per share (EPS) guidance of $5.10-5.20 for the period, compared to the Thomson Reuters consensus estimate of $4.87. The company issued revenue guidance of $23.7-24.2 billion, compared to the consensus revenue estimate of $23.43 billion.
What price target have analysts set for LLY?
18 brokerages have issued twelve-month price objectives for Eli Lilly And Co's shares. Their predictions range from $78.00 to $115.00. On average, they anticipate Eli Lilly And Co's stock price to reach $94.75 in the next year. This suggests a possible upside of 5.2% from the stock's current price. View Analyst Ratings for Eli Lilly And Co.
What is the consensus analysts' recommendation for Eli Lilly And Co?
18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly And Co in the last year. There are currently 9 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Eli Lilly And Co stock?
Here are some recent quotes from research analysts about Eli Lilly And Co stock:
- 1. According to Zacks Investment Research, "Lilly’s new products like Trulicity, Taltz, Basaglar, Cyramza, Jardiance and Lartruvo have been driving revenues and the trend is expected to continue in 2018. Lilly expects to launch 20 new products by 2023, including at least two new indications/line extensions on an average every year. The decision to sell or spin-off the Animal Health segment, which has underperformed lately, is a prudent decision in our view. The stock has outperformed the industry this year so far. However, competitive pressure on Lilly’s drugs is expected to rise this year. Challenges remain for the company in the form of upcoming loss of patent exclusivity for products like Cialis and the impact of generic competition for Strattera, Effient and Axiron. U.S. pricing access pressure will also remain a headwind in 2018. Estimates have gone up slightly ahead of the Q2 earnings release. Lilly has a positive record of earnings surprises in recent quarters." (7/18/2018)
- 2. Cantor Fitzgerald analysts commented, ". We reaffirm our OW rating and $100 12-month PT for LLY’s stock after hosting a conference call with two endocrinologists who disagree on the outcome for LLY’s REWIND trial. We have previously spoken with four physicians, two of which we hosted for this call. Trulicity is one of Lilly’s largest assets. FactSet consensus shows a five-year CAGR for Trulicity (2018-23) of ~9.9%. Based on our calls, most of the physicians expect a positive outcome for REWIND. This could increase Rxs by 20-30% or by multiples of current sales, which leads us to believe that significant upside remains in the drug, if the doctors are right. We expect top-line data by year-end 2018, and a presentation at ADA in June 2019." (7/17/2018)
Who are some of Eli Lilly And Co's key competitors?
Some companies that are related to Eli Lilly And Co include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Sanofi (SNY), GlaxoSmithKline (GSK), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Allergan (AGN) and Shire (SHPG).
Who are Eli Lilly And Co's key executives?
Eli Lilly And Co's management team includes the folowing people:
- Mr. David A. Ricks, Chairman, CEO & Pres (Age 50)
- Mr. Michael J. Harrington, Sr. VP & Gen. Counsel (Age 55)
- Mr. Enrique A. Conterno, Sr. VP (Age 51)
- Mr. Joshua L. Smiley, Sr. VP & CFO (Age 48)
- Mr. Donald A. Zakrowski, Chief Accounting Officer and VP of Fin.
Has Eli Lilly And Co been receiving favorable news coverage?
News headlines about LLY stock have been trending somewhat positive on Wednesday, according to Accern Sentiment. The research firm rates the sentiment of news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Eli Lilly And Co earned a coverage optimism score of 0.12 on Accern's scale. They also assigned media headlines about the company an impact score of 47.75 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.
Who are Eli Lilly And Co's major shareholders?
Eli Lilly And Co's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Lilly Endowment Inc. (11.24%), Bank of Montreal Can (0.38%), Fisher Asset Management LLC (0.34%), Hexavest Inc. (0.12%), DnB Asset Management AS (0.09%) and NN Investment Partners Holdings N.V. (0.08%). Company insiders that own Eli Lilly And Co stock include Alfonso G Zulueta, Christi Shaw, Daniel Skovronsky, Derica W Rice, Donald A Zakrowski, Enrique A Conterno, Jackson P Tai, Jeffrey N Simmons, Joshua L Smiley, Lilly Endowment Inc, Maria A Crowe, Melissa S Barnes, Michael J Harrington, R David Hoover and Susan Mahony. View Institutional Ownership Trends for Eli Lilly And Co.
Which major investors are selling Eli Lilly And Co stock?
LLY stock was sold by a variety of institutional investors in the last quarter, including Lilly Endowment Inc., Bank of Montreal Can, Retirement Systems of Alabama, NN Investment Partners Holdings N.V., Hexavest Inc., Meag Munich Ergo Kapitalanlagegesellschaft MBH, State of Alaska Department of Revenue and Tokio Marine Asset Management Co. Ltd.. Company insiders that have sold Eli Lilly And Co company stock in the last year include Alfonso G Zulueta, Christi Shaw, Donald A Zakrowski, Enrique A Conterno, Jeffrey N Simmons, Joshua L Smiley, Lilly Endowment Inc and Susan Mahony. View Insider Buying and Selling for Eli Lilly And Co.
Which major investors are buying Eli Lilly And Co stock?
LLY stock was acquired by a variety of institutional investors in the last quarter, including DnB Asset Management AS, Fisher Asset Management LLC, Manning & Napier Group LLC, Oakbrook Investments LLC, Farmers Trust Co., Park National Corp OH, Private Asset Management Inc. and IFM Investors Pty Ltd. Company insiders that have bought Eli Lilly And Co stock in the last two years include Daniel Skovronsky, Jackson P Tai and R David Hoover. View Insider Buying and Selling for Eli Lilly And Co.
How do I buy shares of Eli Lilly And Co?
Shares of LLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Eli Lilly And Co's stock price today?
One share of LLY stock can currently be purchased for approximately $90.08.
How big of a company is Eli Lilly And Co?
Eli Lilly And Co has a market capitalization of $96.68 billion and generates $22.87 billion in revenue each year. The company earns $-204,100,000.00 in net income (profit) each year or $4.28 on an earnings per share basis. Eli Lilly And Co employs 40,655 workers across the globe.
How can I contact Eli Lilly And Co?
Eli Lilly And Co's mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The company can be reached via phone at 317-276-2000 or via email at [email protected]
MarketBeat Community Rating for Eli Lilly And Co (NYSE LLY)
MarketBeat's community ratings are surveys of what our community members think about Eli Lilly And Co and other stocks. Vote "Outperform" if you believe LLY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LLY will underperform the S&P 500 over the long term. You may vote once every thirty days.
